The new COVID-19 variant PJ.2.1 is a fast-growing descendant of the JN.1 family of SARS-CoV-2 that was first sampled in Ontario, Canada, in May 2026 and has since been reported in the United States, Europe, Israel, Singapore, Australia and New Zealand. Headlines in November 2026 have made many people in Hyderabad ask whether they should worry. This guide explains, in plain language, what PJ.2.1 is, what the research actually shows, which symptoms to watch for, who is at higher risk and how to protect yourself and your family.
Quick answer
PJ.2.1 is a “saltation” variant of SARS-CoV-2 that descends from MC.10.1.7, part of the JN.1 lineage. It was first sampled in Ontario, Canada, on 2 May 2026 and made up 25.2% of sequenced samples in Ontario between 20 September and 17 October 2026. Laboratory work suggests it binds the ACE2 receptor more efficiently, but it does not appear to escape vaccine antibodies much more than other recent variants, and there is no evidence so far that it causes more severe illness. As of mid-November 2026, its detection in India has not been publicly confirmed. Symptoms are the familiar COVID-19 symptoms: fever, sore throat, cough, runny nose, body ache and tiredness.
Last updated: November 2026 · Reading time: about 13 minutes
What Is the PJ.2.1 Variant?
PJ.2.1 is a sub-lineage of SARS-CoV-2, the coronavirus that causes COVID-19. Scientists place it in the JN.1 family, the group of Omicron descendants that has dominated the world since early 2024. Its direct ancestor is a lineage called MC.10.1.7; “PJ” is simply a short alias that the Pango naming system gives to long lineage names so they stay readable.
What makes PJ.2.1 stand out is not its name but its spike protein, the part of the virus that latches onto human cells. Researchers describe it as a saltation variant, meaning it appeared with a cluster of new spike changes at once rather than picking them up one by one. Variants like this are watched closely because a big jump in the spike can change how easily the virus spreads or how well antibodies recognise it.
| Feature | PJ.2.1 at a glance |
|---|---|
| Virus | SARS-CoV-2 (causes COVID-19) |
| Family | Omicron, JN.1 lineage |
| Parent lineage | MC.10.1.7 |
| Type | Saltation variant with a highly mutated spike |
| First sample | Ontario, Canada, 2 May 2026 |
| WHO status (Nov 2026) | Being monitored; not listed as a Variant of Interest or Variant Under Monitoring on the WHO tracking page |
| Severity | No evidence of more severe disease so far |
Where and When Was PJ.2.1 Found?
The variant was picked up through routine genomic surveillance, the same kind of sequencing India runs through INSACOG. Here is how it has been reported so far:
| Date (2026) | Event |
|---|---|
| 2 May | First documented PJ.2.1 sample collected in Ontario, Canada |
| 30 June | First identified in the United States, in New York City |
| July to October | Detected in more Canadian provinces (Alberta, British Columbia, New Brunswick) and several US states |
| September to October | Reported in Spain, France, Israel, Singapore, Australia and New Zealand; signs of local community transmission in parts of Spain |
| 24 October | German study by Markus Hoffmann and colleagues on PJ.2.1 published in the Journal of Infection |
| Early November | WHO says it is closely monitoring PJ.2.1 and that symptoms resemble a cold or flu; its regional office says the risk of wider spread is increasing |
How Fast Is PJ.2.1 Spreading?
The clearest numbers come from Public Health Ontario, where PJ.2.1 was first found. Its share of sequenced COVID-19 samples has risen steadily for four months:
| Sampling period (2026) | Share of sequenced samples that were PJ.2.1 |
|---|---|
| 28 June to 25 July | 1.1% |
| 26 July to 22 August | 3.5% |
| 23 August to 19 September | 16.9% |
| 20 September to 17 October | 25.2% (132 of 523 sequenced cases) |
A rising share means PJ.2.1 is out-competing other variants in that population, which is called a growth advantage. It does not automatically mean more people are getting sick overall, and Public Health Ontario notes that recent sequencing data may be incomplete and may not represent the whole population. The German research team also found PJ.2.1 spreading in the USA, Canada and Spain, and, like most current variants, it mainly infects people aged 60 and above in surveillance data.
Why this matters: when one variant keeps gaining ground for several months, it often becomes the next dominant strain in other countries too. That is why health agencies watch PJ.2.1, even though it is not yet proven to cause more serious illness.
Is PJ.2.1 in India?
As of mid-November 2026, there is no verified public confirmation that PJ.2.1 has been detected in India. The Indian SARS-CoV-2 Genomics Consortium (INSACOG), which sequences samples from laboratories across the country, has not listed it as a confirmed Indian detection on its public dashboard.
That can change quickly. International travel links India with every country where PJ.2.1 has been found, and previous JN.1-family variants reached India within weeks of spreading abroad. The practical message for families in Hyderabad is simple: do not panic, but do not ignore respiratory symptoms either, especially in older or medically vulnerable relatives. Rely on announcements from the Ministry of Health and Family Welfare, ICMR and the Telangana health department rather than forwarded social media messages.
What Does the Research Say About PJ.2.1?
The most detailed study so far comes from a team in Germany led by Markus Hoffmann and Stefan Pöhlmann, first shared as a preprint and then published in the Journal of Infection on 24 October 2026. They compared PJ.2.1 with other recent variants in the laboratory. Their key findings were:
- Better cell entry: PJ.2.1’s spike appears to use the ACE2 receptor on human cells more efficiently than the reference variant LP.8.1. It was less affected by an antibody that blocks ACE2, which the authors interpret as stronger receptor binding.
- Little extra immune escape: blood samples from people who had received an LP.8.1-adapted COVID-19 vaccine still neutralised PJ.2.1. Neutralisation was about 1.8 times lower than against LP.8.1, a modest drop that the authors say is no greater than for most other variants they tested.
- A likely explanation: the researchers suggest that improved ACE2 binding, rather than antibody escape, may be the main reason PJ.2.1 is spreading quickly.
What we know
- PJ.2.1 belongs to the JN.1 family
- It is gaining ground in Canada, the US and Spain
- It binds human cells efficiently in lab tests
- Updated vaccine antibodies still neutralise it
- WHO is monitoring it closely
What we do not yet know
- Whether it causes more or less severe illness (no evidence of more so far)
- Whether it will become dominant worldwide
- How widely it is circulating in India
- How long protection from recent infection or vaccination lasts against it
- Whether lab findings translate into real-world transmission
Laboratory results are an early signal, not the final word. Real-world data on hospital admissions and deaths take longer to collect, which is why public health agencies use cautious language at this stage.
What Is a Saltation Variant, and Why Do Scientists Watch Them?
Most coronavirus variants evolve in small steps, adding one or two mutations at a time. A saltation variant takes a big leap, appearing with many new spike changes at once. Scientists think such jumps often happen during long-lasting infections in people with weakened immune systems, where the virus has months to adapt before spreading again.
The world has seen this pattern before. In 2023, the heavily mutated BA.2.86 variant appeared suddenly; one of its descendants, JN.1, went on to dominate globally in 2024 and is the ancestor of most variants circulating today, including PJ.2.1. Not every saltation variant takes off, though. In 2026 the WHO noted that another saltation lineage, BA.3.2, was rising in some places but appeared to have lower fitness than JN.1 descendants and had not caused a substantial increase in disease. PJ.2.1 is being watched for the same reasons, and so far it is behaving like a variant that spreads well rather than one that makes people sicker.
PJ.2.1 Symptoms: What to Watch For
There are no symptoms unique to PJ.2.1. The WHO says its symptoms resemble a cold or flu, and they match those of other recent COVID-19 variants. Commonly reported symptoms include:
1. Fever or chills
Often mild to moderate; may last two to three days. Check temperature twice a day if you are unwell.
2. Sore throat
A scratchy or painful throat is one of the most frequent early symptoms of recent Omicron variants.
3. Cough
Usually dry at first; may linger for one to three weeks after other symptoms settle.
4. Runny or blocked nose
Easily mistaken for a common cold or seasonal allergy.
5. Tiredness
Marked fatigue is common and can persist for a while after the infection clears.
6. Headache and body ache
Muscle pain and headache are typical in the first few days.
7. Loss of taste or smell
Less common with recent variants than in 2020 to 2021, but still possible.
8. Stomach upset
Some people have nausea, loose stools or poor appetite, especially older adults.
Because these symptoms overlap with influenza, other respiratory viruses and even early dengue during Hyderabad’s post-monsoon months, symptoms alone cannot tell you which virus you have. A test is the only reliable way to confirm COVID-19.
PJ.2.1 vs Flu, Common Cold and Dengue
In Hyderabad, October and November bring a mix of viral fevers. This comparison shows typical patterns, but there is a lot of overlap, so use it as a guide rather than a diagnosis:
| Feature | COVID-19 (incl. PJ.2.1) | Influenza | Common cold | Dengue |
|---|---|---|---|---|
| Onset | Gradual or sudden | Sudden | Gradual | Sudden high fever |
| Fever | Common, often mild to moderate | Common, often high | Uncommon or low | High, often 39 to 40°C |
| Sore throat / runny nose | Common | Common | Very common | Uncommon |
| Cough | Common | Common | Mild | Uncommon |
| Body ache | Common | Severe | Mild | Severe, with pain behind the eyes |
| Key test | Rapid antigen or RT-PCR | Influenza test (on doctor’s advice) | Usually none needed | NS1 antigen, IgM, platelet count |
Local tip: if you have high fever with severe body ache and no cough or cold, ask your doctor about dengue testing as well. See our guides on viral fever and sore throat for more.
Is PJ.2.1 More Dangerous Than Earlier Variants?
So far, no. The WHO has said there is currently no evidence that PJ.2.1 causes more severe COVID-19 than other lineages, and as of November 2026 there are not enough data to show higher rates of hospitalisation, complications or death. Most healthy, vaccinated or previously infected adults are expected to have a mild to moderate illness that settles in about a week.
That said, any COVID-19 variant can be serious for certain people. Those at higher risk include:
- Adults aged 60 years and above, who also make up most PJ.2.1 infections in surveillance data
- People with diabetes, especially if blood sugar is poorly controlled
- People with heart disease, high blood pressure, chronic kidney disease or chronic lung disease such as asthma or COPD
- People with a weakened immune system, including those on chemotherapy, steroids or transplant medicines
- Pregnant women
- People with obesity
⚠️ Seek medical care the same day (or go to an emergency department) if you or a family member has:
- Difficulty breathing or breathlessness at rest or while talking
- Oxygen saturation below 94% on a pulse oximeter, or a falling trend
- Chest pain or pressure that does not go away
- Confusion, drowsiness or difficulty waking up
- Bluish lips or face
- Fever lasting more than three days, or returning after improving
- In people with diabetes: very high or very low blood sugar, vomiting or inability to eat
Testing: What to Do If You Have Symptoms
Routine tests cannot tell you whether you have PJ.2.1 specifically; identifying the variant needs genomic sequencing, which is done for surveillance, not for individual care. What matters for you is whether you have COVID-19 at all. This flowchart shows a sensible approach:
Breathlessness, chest pain, confusion, SpO2 below 94%
Home kit or lab
Repeat after 48 hours or ask for RT-PCR
See a doctor early: antivirals work best in the first few days
Rest, fluids, isolate from vulnerable people, watch for red flags
Treatment and Home Care
Treatment for PJ.2.1 is the same as for other current COVID-19 variants. Most people recover at home with supportive care:
- Rest and fluids: drink water, buttermilk, coconut water, soups or oral rehydration solution (ORS), especially if you have fever or loose stools.
- Fever and pain relief: paracetamol is usually suitable; ask your doctor or pharmacist about the right dose for you, particularly if you have liver disease.
- Throat comfort: warm salt-water gargles, steam inhalation and warm drinks can ease a sore throat and blocked nose.
- Monitor: check temperature and, if you have a pulse oximeter, oxygen saturation twice daily; people with diabetes should check blood sugar more often, because infections can push it up.
- Isolate sensibly: stay away from older or medically vulnerable family members while you have symptoms, and wear a mask if you must be around others.
For people at high risk of severe illness, the WHO recommends that doctors consider oral antiviral treatment, such as nirmatrelvir-ritonavir, ideally started within the first five days of symptoms. These medicines interact with many common drugs (including some heart, cholesterol and blood-thinning medicines), so they must only be taken on a doctor’s prescription.
Avoid: antibiotics without a doctor’s advice (they do not work against viruses and add to antibiotic resistance), self-medicating with steroids, and unproven remedies promoted on social media.
Do COVID-19 Vaccines Work Against PJ.2.1?
The available evidence suggests updated vaccines still offer useful protection. In the German study, antibodies from people who received an LP.8.1-adapted vaccine neutralised PJ.2.1, with only a modest 1.8-fold reduction compared with LP.8.1. In May 2026, the WHO’s Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) named monovalent LP.8.1 as the recommended vaccine antigen, while noting that other antigens such as XFG or NB.1.8.1 could also be used if they produce broad responses.
COVID-19 vaccines are best at preventing severe disease, hospitalisation and death rather than every infection. The WHO continues to recommend vaccination for the people most at risk: older adults, people with chronic illnesses, immunocompromised people and pregnant women. Availability of updated COVID-19 vaccines varies in India, so if you are in a high-risk group, ask your doctor whether a booster is advisable and available for you. The same appointment is a good time to discuss your annual influenza vaccine.
How to Protect Yourself and Your Family
The basic measures that worked against earlier variants still work against PJ.2.1:
1. Ventilate indoor spaces
Open windows and use fans to move air, especially in crowded rooms, offices and classrooms.
2. Mask when it counts
Wear a well-fitting mask in crowded indoor places and hospitals, and when visiting elderly or sick relatives.
3. Wash hands
Use soap and water or an alcohol-based sanitiser, particularly before eating and after travel.
4. Stay home when sick
Limit contact with others while you have symptoms, and keep children with fever home from school.
5. Protect the vulnerable
If an older or chronically ill family member lives with you, be extra careful when anyone in the house is unwell.
6. Keep chronic illness controlled
Good control of diabetes, blood pressure and lung disease lowers the risk of complications from any infection.
Helpful reading: our full body check-up guide explains which routine tests help keep chronic conditions under control.
PJ.2.1 Myths vs Facts
| Myth | Fact |
|---|---|
| PJ.2.1 is a deadly new virus. | It is a sub-lineage of the same SARS-CoV-2 virus, and there is no evidence it causes more severe illness. |
| Vaccines do not work against PJ.2.1. | Lab studies show updated vaccine antibodies still neutralise it, with only a modest reduction. |
| PJ.2.1 has specific symptoms like a severe sore throat. | No symptom is unique to PJ.2.1; its symptoms overlap with other COVID-19 variants and flu. |
| A negative home test means it is not COVID. | One negative rapid test does not rule it out; repeat after 48 hours or ask for RT-PCR if symptoms continue. |
| Antibiotics help recovery. | Antibiotics do not act on viruses and should only be used if a doctor finds a bacterial infection. |
| PJ.2.1 is already spreading widely in India. | As of mid-November 2026, its detection in India has not been publicly confirmed. |
When to See a Doctor in Hyderabad
Most people with mild COVID-like symptoms can recover at home, but see a doctor early if you are in a high-risk group, if symptoms are getting worse after three days, or if you have any red-flag sign. Early review matters most for older adults and people with diabetes, heart disease or kidney disease, because antiviral treatment and closer monitoring work best in the first few days.
In west Hyderabad, Dr. Ram Kumar, a general physician and diabetologist with more than 15 years of experience, consults at Apollo Clinic, Narsingi, and can assess fever and respiratory symptoms, arrange testing and help people with diabetes or other chronic conditions manage their health during an infection. Read more in our guide to the best physician in Narsingi. For breathing difficulty, chest pain or confusion, go straight to the nearest hospital emergency department or call 108.
Frequently Asked Questions
What is the new COVID variant PJ.2.1?
PJ.2.1 is a sub-lineage of SARS-CoV-2 in the JN.1 family that descends from MC.10.1.7. It was first sampled in Ontario, Canada, on 2 May 2026 and is described as a saltation variant because it carries many new spike-protein changes.
Is PJ.2.1 dangerous?
There is currently no evidence that PJ.2.1 causes more severe COVID-19 than other variants. The WHO is monitoring it because it is spreading quickly, but most people are expected to have mild to moderate illness. Older adults and people with chronic conditions should still take precautions.
What are the symptoms of PJ.2.1?
PJ.2.1 symptoms are the same as other recent COVID-19 variants: fever, sore throat, cough, runny or blocked nose, tiredness, headache and body ache. The WHO says they resemble a cold or flu, so only a test can confirm COVID-19.
Has PJ.2.1 been found in India?
As of mid-November 2026, PJ.2.1 has not been publicly confirmed in India, and INSACOG has not listed it as an Indian detection. Follow updates from the Ministry of Health and Family Welfare and ICMR.
Do COVID vaccines protect against PJ.2.1?
Yes, updated vaccines appear to offer useful protection. Antibodies from people given an LP.8.1-adapted vaccine still neutralised PJ.2.1 in laboratory tests, with only about a 1.8-fold reduction compared with LP.8.1.
Can a rapid antigen test detect PJ.2.1?
Rapid antigen and RT-PCR tests detect COVID-19 caused by current variants, including PJ.2.1, but they do not tell you which variant you have. If a rapid test is negative and you still have symptoms, repeat it after 48 hours or ask for an RT-PCR test.
Where did the PJ.2.1 variant originate?
The first documented PJ.2.1 sample was collected in Ontario, Canada, on 2 May 2026. It has since been reported in the United States, Spain, France, Israel, Singapore, Australia and New Zealand.
Sources and Further Reading
- World Health Organization. Tracking SARS-CoV-2 variants. Updated 2026.
- World Health Organization. Statement on the antigen composition of COVID-19 vaccines. 16 May 2026.
- Hoffmann M, Zhang L, Chen N, et al. Epidemiology and virological characteristics of the emerging SARS-CoV-2 variant PJ.2.1. bioRxiv preprint, October 2026 (published in Journal of Infection).
- Bernama. WHO says new COVID-19 variant symptoms resemble cold, flu. 8 November 2026.
- Open Magazine. New COVID-19 variant PJ.2.1 spreads across countries: symptoms, risks and what the research says. November 2026.
- Adda247. New COVID-19 variant PJ.2.1: symptoms, spread, vaccine findings and key facts (Public Health Ontario data summary). November 2026.
This article provides general health information based on research and public health reports available in November 2026. Knowledge about new variants changes quickly. It does not replace an individual medical assessment; if you have symptoms or concerns, please consult a qualified doctor.
